Clear Street Reiterates Buy Rating on Palvella Therapeutics (PVLA) following BEYOND mLM disease-awareness campaign launch

March 10, 2026 12:23 PM

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $220.00 price target on Palvella Therapeutics (NASDAQ: PVLA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found